GVR Report cover Diabetic Foot Ulcer Treatment Market Size, Share & Trends Report

Diabetic Foot Ulcer Treatment Market Size, Share & Trends Analysis Report By Treatment (Biologics, Wound Care Dressings, Therapy Devices), By Ulcer Type (Ischemic, Neuro-Ischemic, Neuropathic), And Segment Forecasts, 2019 - 2025

  • Report ID: GVR-2-68038-742-1
  • Number of Pages: 90
  • Format: Electronic (PDF)
  • Historical Range: 2016 - 2017
  • Industry: Healthcare

Report Overview

The global diabetic foot ulcer treatment market size was valued at USD 3.6 billion in 2017. It is anticipated to expand at a CAGR of 8.2% over the forecast period. The rising prevalence of diabetes and the rapidly growing geriatric population worldwide are among the primary growth stimulants for DFU treatment market. A diabetic foot ulcer is one of the major complications of diabetes mellitus, which forms a major characteristic of diabetic foot.

U.S. diabetic foot ulcer treatment market

Healing of wounds is typically an innate mechanism. However, certain metabolic disorders such as diabetes mellitus delay the typical pace of the wound healing process. Diabetic foot ulcers are most commonly caused by irritated or wounded feet, nerve damage, poor circulation, and high blood sugar (hyperglycemia). Unusual swelling, redness, irritation, and stench on one or both feet are common initial symptoms of foot ulcers.

DFU treatments, usually include control of blood sugar, removal of dead tissue, wound dressings, and negative pressure therapy. Hyperbaric oxygen therapy may be beneficial but is costly and in some cases, surgery may also improve results. These ulcers are responsible for more than 80.0% of all diabetes-related lower-leg amputations and occur in around 15.0% of diabetic patients.

The high cost of ulcer management has been restricting the market from realizing its utmost potential. Many developing and underdeveloped countries demonstrate a lack of healthcare facilities, subsequently limiting the market growth. However, the adoption of novel therapeutics improved biologics, and continued prioritization to avoid surgeries and amputations are estimated to offset limitations affecting the growth of the market. Thus, in turn, offering significant opportunities for the market to generate revenue.

Treatment Insights

On the basis of treatment, the market has been categorized into wound care dressings, biologics, therapy devices, antibiotic medications, and others. Biologics dominated the market, followed by wound care dressings in 2017. They have been divided into growth factors and skin grafts. Biologics are expected to register the highest CAGR during the forecast period.

Wound care dressings have been further segmented into alginate dressings, Hydrofiber dressings, foam dressings, film dressing, hydrocolloid dressings, surgical dressings, and hydrogel dressings. Foam dressings were at the forefront among different types of wound care dressings in 2017. Therapy devices have been bifurcated into negative pressure wound therapy and ultrasound therapy. Spiraling adoption of medical devices for an efficacious, better targeted, and safer treatment of patients is likely to create an upswing in the demand for diabetic foot ulcer therapy devices.

Ulcer Type Insights

The global DFU treatment market has been categorized into neuropathic, ischemic, and neuro-ischemic ulcers. According to various studies in the 1980s, neuropathy was the leading cause responsible for diabetic foot ulcers. However, in the last two decades, there has been an increase in the number of cases of neuro-ischemic or ischemic ulceration in the last two decades.

North America diabetic foot ulcer treatment market

Neuro-ischemic ulcers are the most prevailing among three types, followed by neuropathic and ischemic. Neuro-ischemic ulcers accounted for the largest share of the market in 2017. Through the forecast period, they are projected to exhibit the fastest growth, followed by neuropathic ulcers.

Regional Insights

North America led the market in 2017. The rising cohort of diabetic patients and adequate healthcare facilities in the region are key factors responsible for the growth of the regional market. Long R&D and approval cycles are required due to the capital-intensive nature of North America, which acts as a stumbling stone for the growth of the market in the region. However, the rising adoption of novel biologics and wound care devices for the treatment of these ulcers is contributing to the dominance of North America.

Europe held the second-largest share in the market, followed by the Asia Pacific. APAC will exhibit the highest CAGR during the forecast period. The increasing prevalence of diabetes and a large geriatric population base in both India and China are supporting the growth of the regional market. This can also be attributed to increased adoption and favorable legislation in developed economies such as Japan and Australia.

Key Companies & Market Share Insights

Some of the prominent companies operating in the market are ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast A/S; Smith & Nephew Plc.; B. Braun Melsungen AG; Medline Industries, Inc.; Medtronic Plc.; Organogenesis, Inc.; Molnlycke Health Care AB; and BSN Medical GMBH. The players focus on alliances, strategic planning, new treatment planning, and research activities to achieve favorable growth. Currently, Smith & Nephew, Coloplast, CovanTec, Acelity, and 3M Healthcare are leading the market, supported by strong sales of their marketed therapeutic options for the treatment of diabetic foot ulcers.

Potential launches of promising late-stage pipeline products such as FirstString Research’s Granexin gel, ViroMed’s VM 202, and Oneness Biotech’s WH-1 ointment will further drive the market. Few of the other players actively investing in this arena include Centaur Pharmaceuticals Pvt. Ltd.; MediWound Ltd.; Izun Pharmaceuticals Corp.; Issar Pharmaceuticals Pvt. Ltd.; Novalead Pharma Pvt. Ltd.; Karyopharm Therapeutics Inc.; Aurealis Pharma AG; Stratatech Corp.; and ZZ Biotech, LLC.

Diabetic Foot Ulcer Treatment Market Report Scope

Report Attribute


Market size value in 2020

USD 4.6 billion

Revenue forecast in 2025

USD 6.82 billion

Growth Rate

CAGR of 8.2% from 2018 to 2025

Base year for estimation


Historical data

2016 - 2017

Forecast period

2018 - 2025

Quantitative units

Revenue in USD million and CAGR from 2018 to 2025

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

Segments covered

Treatment, ulcer type, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; Japan; China; India; Brazil; Mexico; South Africa

Key companies profiled

ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast A/S; Smith & Nephew Plc.; B. Braun Melsungen AG; Medline Industries, Inc.; Medtronic Plc.; Organogenesis, Inc.; Molnlycke Health Care AB; BSN Medical GMBH

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on industry trends in each of the sub segments from 2016 to 2025. For the purpose of this study, Grand View Research has segmented the global diabetic foot ulcer treatment market report on the basis of treatment, ulcer type, and region:

  • Treatment Outlook (Revenue, USD Million, 2016 - 2025)

    • Wound Care Dressings

      • Alginate Dressings

      • Hydrofiber Dressings

      • Foam Dressings

      • Film Dressing

      • Hydrocolloid Dressings

      • Surgical Dressings

      • Hydrogel Dressings

    • Biologics

      • Growth Factors

      • Skin Grafts

    • Therapy Devices

      • Negative Pressure Wound Therapy

      • Ultrasound Therapy

    • Antibiotic Medications

    • Others

  • Ulcer Type Outlook (Revenue, USD Million; 2016 - 2025)

    • Neuropathic Ulcers

    • Ischemic Ulcers

    • Neuro-ischemic Ulcers

  • Regional Outlook (Revenue, USD Million; 2016 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • The U.K.

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • MEA

      • South Africa

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.